23andMe nabbed FDA clearance to market its genetic carrier test directly to consumers, a big win for the company as it continues to get back in the agency's good graces and expand the reach for its genetic tests.
Johnson & Johnson's Janssen unit is teaming up with nonprofit JDRF to develop new diagnostic approaches for Type 1 diabetes, aiming to identify the disease earlier and curb its progression. Read more >>
Denmark's Dako is teaming up with Ono Pharmaceutical to develop a test for Ono and Bristol-Myers Squibb's drug for non-small cell lung cancer (NSCLC), Opdivo, adding to its tally of companion diagnostics partnerships and gaining more ground in the field. Read more >>
POPULAR COMMENT THREADS
Exact Sciences is charting big plans for 2015, increasing its sales efforts and pushing for expanded coverage of its stool-based DNA colon cancer test to grab a bigger market share.
Vigilant Biosciences roped in $5.5 million in a Series B round to support development of its diagnostic system for the early detection of oral cancer, giving the company a boost as it eyes European and stateside approval for its product.
Israeli diagnostic outfit Check-Cap raised $24 million in an initial public offering and a simultaneous private placement, giving the company a boost as it looks to develop its disposable imaging capsules for colorectal cancer screening.
The Department of Defense has a habit of funding new medical technologies. This week it awarded a government contractor MRIGlobal $14.8 million for its proposed Sample-to-Sequence system to sequence the entire genome of pathogens and give a diagnosis within 24 hours.
Roche and BioMed X are teaming up to create a diagnostics research group focused on biosensors and nanomaterials such as graphene within BioMed X's open innovation lab in Heidelberg, Germany.
From Our Sister Sites
Petaluma, CA-based Oculus Innovative Sciences announced Thursday that it has launched an animal health unit and 6 new products for the treatment of wounds, skin and eyes.
St. Jude Medical agreed to pay as much as $14.25 million to settle about 950 claims related to its Riata defibrillator leads. The wires used to shock a heart that is beating abnormally degraded in as few as four years and were pulled from the market in 2010.